We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · January 13, 2020

Acalabrutinib Monotherapy in Patients With Relapsed or Refractory CLL



Additional Info

Acalabrutinib Monotherapy in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia: Updated Phase 2 Results
Blood 2019 Dec 26;[EPub Ahead of Print], JC Byrd, WG Wierda, A Schuh, S Devereux, JM Chaves, JR Brown, P Hillmen, P Martin, FT Awan, DM Stephens, P Ghia, J Barrientos, JM Pagel, JA Woyach, K Burke, T Covey, M Gulrajani, A Hamdy, R Izumi, MM Frigault, P Patel, W Rothbaum, MH Wang, S O'Brien, RR Furman

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading